New detalimogene bladder cancer data send the minnow’s stock up 47%.
ApexOnco Front Page
Recent articles
The response rate jumps to 30% with higher doses of IMA402.
First data with Astra’s torvutatug samrotecan come as Lilly unveils its first folate pivotal trial.
The Maestra-2 trial will test INCB123667 in platinum-resistant ovarian cancer.
The ESMO regular abstract lift reveals first human datasets for several projects.
Data with the T-cell engager ASP2138 look lukewarm, but could improve with combos.
And Vironexis’s second gene therapy-encoded T-cell engager will soon go clinical.
The biggest Q3 agreement was AbbVie’s $700m swoop for Glenmark's trispecific T-cell engager.
